NCT03795571

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone (R2-GOD) in Treatment of Relapse/Refractory DLBCL:A Phase I Study

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Previous study showed that Lenalidomide or R-GDP could achieve response in Relapse and Refractory DLBCL.The investigators therefore design this phase I study to investigate the safety and efficacy of R2-GOD in relapsed diffuse large-cell lymphoma.

Conditions

• Diffuse Large B-cell Lymphoma Recurrent
• Diffuse Large B Cell Lymphoma Refractory

Interventions

Type	Name	Description
DRUG	Rituximab	Rituximab 375mg/m2，d0
DRUG	Gemcitabine	Gemcitabine 1000mg/m2，d1，d5
DRUG	Oxaliplatin	Oxaliplatin 75mg/m2，d1
DRUG	Dexamethasone	Dexamethasone 40mg/d，d1\~d4
DRUG	Lenalidomide Oral Capsule	Lenalidomide 10mg/d、15mg/d、20mg/d、25mg/d d1\~d10； 21days a cycle

Timeline

• Start date: 2019-01-01
• Primary completion: 2019-12-31
• Completion: 2019-12-31
• First posted: 2019-01-07
• Last updated: 2019-02-15

Locations

1 site across 1 country: China